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Introduction
Schizophrenia affects approximately 1% of the adult population. 1 Schizophrenia patients have 3 major symptoms: positive symptoms (including delusions and hallucinations), negative symptoms (including anhedonia, the inability to begin and maintain planned activities) and cognitive symptoms (including memory deficits, difficulties in focusing and short attention span). 2 The core treatment for schizophrenia is antipsychotic medications, 3 which do not address 'general functioning', thus maintaining cognitive impairment associated with schizophrenia as an unmet global healthcare problem. 4, 5 Autophagy is a cellular process that preserves the balance between the synthesis, degradation and recycling of cellular components. Autophagy is essential for neuronal survival and function and was recently suggested to play a key role in the pathophysiology of schizophrenia. 6 Several proteins control the autophagy pathway, including BECN1/beclin 1 and MAP1LC3 (LC3 henceforth in the text). BECN1, triggering the formation of autophagosomes via membrane recruitment, 7 exhibits reduced expression in the hippocampus of postmortem schizophrenia subjects but not in peripheral lymphocytes. 6 LC3, serving as a marker for autophagy, is cleaved at the C terminus to become LC3-I and is transformed by conjugation to phosphatidylethanolamine (PE) to produce LC3-II. LC3-II connects to the phagophore membrane. 8 ADNP, an essential protein for brain formation, 9, 10 interacts with LC3.
This interaction is increased in the presence of the short ADNP peptide and the therapeutic drug candidate NAP. 6 In contrast to BECN1, the expression of Adnp and its family member Adnp2, [11] [12] [13] [14] which is deregulated in postmortem hippocampal samples from schizophrenia subjects, 15 showed significantly increased expression in lymphocytes from related patients. Such augmentation is similar to increases in the antiapoptotic protein BCL2/B cell leukemia/lymphoma 2, which is known to interact with BECN1. The increase in ADNP was associated with the initial stages of the disease, possibly reflecting a compensatory effect. The increase in ADNP2 might be a consequence of neuroleptic treatment, as observed in rats subjected to CLZ treatment. 6 Genome-wide association analysis encompassing thousands of schizophrenia patients has identified risk loci for schizophrenia. Identified genes included those encoding proteins associated with calcium, glutamate and N-methyl-Daspartate/NMDA signaling in addition to protein degradation, cytoskeleton and synapse assembly. 16, 17 In this respect, ADNP may affect schizophrenia, in part through interaction with microtubules. 18, 19 Adnp haploinsufficiency results in cognitive and social deficits, paralleled by microtubule-associated pathology, and treatment with the ADNP snippet NAP (a microtubule-stabilizer) provides partial protection from these effects. 20, 21, 22 and pipeline drug candidates. 23, 24 Adnp haploinsufficiency is also associated with decreased hippocampal Becn1 expression. 6 It remains to be observed if NAP and/or pipeline products can protect against BECN1 deficiency.
Schizophrenia is now conceptualized as a syndrome with distinguishable symptoms, such as psychosis, cognitive dysfunction, and negative symptoms. This description has been extended to animals, thus allowing for the possibility of identifying animal models of schizophrenia and/or the aforementioned manifestations of the disorder. Map6-deficient mice fulfill the criteria of the above model. Indeed,
Map6
-deficient mice exhibit severe behavioral disorders that can be linked to positive and negative symptoms in addition to cognitive dysfunction. [25] [26] [27] [28] [29] [30] [31] [32] 3) Will CLZ mimic the NAP effect or will a combination be beneficial?
We postulate that a combination of NAP and CLZ may provide not only inhibition of psychosis (CLZ) but also functional strengthening of activities of daily living and rational cognitive behavior (NAP). 23 Neither NAP nor combination treatment affected Adnp RNA expression.
Results
Map6
However, NAP treatment resulted in a slight reduction in Adnp2 levels, which was not apparent in combination with CLZ ( Fig. 2C and D, *P<0.05). Interestingly, previous results have shown a deregulation of ADNP and ADNP2 in schizophrenia with ADNP2
RNA levels increasing in the hippocampus of the postmortem brains in parallel with disease duration. 15 Our current results suggest that NAP treatment may protect against this deregulation.
These results prompted further experiments to evaluate and correlate behavioral outcomes to protein expression with an emphasis on autophagy.
Map6 +/-mice hyperactivity in the open field is normalized by NAP + CLZ combination treatment
As previously described, 43 Map6 +/-mice suffer from hyperactivity compared to The schizophrenic-like preference to familiar rather than novel objects typically exhibited by Map6 +/-mice is normalized by NAP + CLZ combination treatment
The object recognition and discrimination test, based on visual discrimination between two different objects, measures object-related memory, which is deficient in schizophrenia. 48 Although one may measure several schizophrenia-related behavioral deficits, as elegantly reviewed, 48 we concentrated on object recognition, as our previous data showed an association of Map6-deficiency with reduced performance in the object recognition test. 43 Here, we extended these studies; Map6 +/-mice were not able to discriminate the familiar object from the novel object and preferred the familiar object, an observation that was in contrast to the control Map6 +/+ mice ( Interestingly, the NAP-treated Map6 +/-mice exhibited an even greater discrimination index compared to the Map6 +/+ mice ( Fig. 4A versus 4C ). However, with the combination treatment of NAP + CLZ, the mice showed almost identical scores compared to those of the Map6 +/+ mice (normal naïve mice).
CLZ toxicity and NAP protection
Published literature links CLZ to neuronal cell death in vitro, 49 which may be prevented by NAP treatment. 50 Using the neuronal human SH-SY5Y neuroblastoma cell line, we set out to verify 1) whether CLZ indeed harms neuronal-like cellular viability and 2) whether NAP reduces cell death caused by CLZ treatment. Human SH-SY5Y neuroblastoma cells were exposed to NAP (10 -15 M to 10 -11 M) for 24 h at 37 °C either in the absence or in the presence of 20 μg/ml CLZ. 49 The measurement of metabolic activity/viability was performed by a cell proliferation assay (MTS). NAP hippocampus from schizophrenia subjects compared to that in the controls. 6 These similarities between findings in mouse and human strengthen the validity of the Interestingly, the loss of MAP6 protein in map6-null mice impairs peripheral olfactory neurogenesis. 53 Thus, Map6-deficient olfactory neurons showed presynaptic swellings with autophagic-like structures. In olfactory and lvomeronasal epithelia, there was an increase in neuronal turnover, as shown by an increase in the number of proliferating, apoptotic and immature cells with no changes in the number of mature neurons. Similar alterations in peripheral olfactory neurogenesis have also been described in schizophrenia patients. 54 Furthermore, regeneration resulted in the abnormal organization of olfactory terminals within the olfactory glomeruli in map6-null mice. 53 These complementary studies, compared to ours, suggest regional variations in neuronal regulation with abnormalities in the autophagic and apoptotic mechanisms resulting from MAP6 deficiencies, which may mimic the clinical/pathological manifestation in schizophrenia.
Our immunohistochemical data expanded upon the biochemical analyses,
showing a marked decrease in the number of cells expressing BECN1 in the hippocampus of the naïve Map6 +/-mice compared to that in the naïve Map6 +/+ mice.
The autophagic process is in a crossroad between cell viability and apoptosis; we hypothesize that the deregulation of autophagy induces cell death. The putative effects on autophagy are consistent with NAP protection against apoptosis, which includes protection against caspase activation, as observed in our previous studies 55, 50 and mitochondrial CYCS/cytochrome C release 56 in association with the microtubulecytoskeleton protection.
Interestingly, previous findings show an inhibitory effect of schizophrenia drugs, including CLZ, on the autophagic process 51 and the inhibition of autophagy by the recruitment of BECN1 to the microtubules. 57 Here, we showed that NAP alone and in combination with CLZ increased Becn1 expression. We suggest that to effectively treat schizophrenia, it is necessary for the cell to have adequate cytoskeleton, BECN1 expression and apoptosis to provide for an efficient process of autophagy and/or other BECN1-related processes. Furthermore, the schizophrenia-related deregulation of ADNP and ADNP2 expression that has previously been observed in the human hippocampus was recapitulated here to a certain degree in the Map6 +/-mouse model. 15 The association of ADNP and its fragment peptide NAP with the microtubule cytoskeleton 58 and the autophagy pathway 6, 52 paves the path to replacement therapy.
Recent clinical studies have shown significant efficacy for NAP treatment on the UCSD Performance-based Skills Assessment of functional activity. 44 Further studies show NAP protection of N-acetylaspartate and choline levels in dorsolateral prefrontal cortex in patients with schizophrenia, suggesting neuroprotection in vivo. 45 These results support the preclinical prediction and suggest future larger clinical testing, combination treatments and further investigation of pipeline products, leading to science-based translational medicine. (Fig. 3B) ; intranasally administered 3) DD, the NAP vehicle 43, 46 (described in the first instance of appearance of this abbreviation (Fig. 2C, legend) ); 4) NAP (Allon Therapeutics, kind gift) in DD (Fig. 3C) and combinations, each administered as above including 5) saline +DD and 6) NAP+CLZ (Fig. 3D) . 43 However, here we wanted to test for a potential synergistic effect; therefore, we reduced the CLZ dose.
Methods and Materials
Animals and treatment
5-month-old
DD was used as a vehicle/placebo for NAP, 46, 43 described in the first instance of appearance of this abbreviation (Fig. 2C, legend) . This placebo solution was administered to mice hand-held in a semisupine position with nostrils facing the investigator. A pipette tip was used to administer 2.5 µl/nostril (total: 0.5 µg/5 µl/mouse/day). The mouse was hand held until the solution was fully absorbed (~10 s).
Behavioral assessments were implemented according to our previous research. 43 In short, on the 4th week of drug application, the open field test was conducted; on the 6th week of drug application, an object recognition test was conducted. After 15 weeks of treatment, the mice were decapitated, and hippocampal tissue was extracted and stored at -80 0 C for biochemical analysis. A second set of brains was used for immunohistochemistry as outlined below. 
Biochemical analyses Extractions
Reverse transcription and quantitative Real-Time PCR
Samples with the same amount of total RNA were used to synthesize single-strand cDNA using qScript™ cDNA Synthesis (Quanta BioSciences, Inc. 95047-100). Primer pairs were designed using the primer 3 web interface (http://frodo.wi.mit.edu/primer3/) and synthesized by Sigma-Genosys (The Woodlands, TX). 
Tissue preparation for histology and immunohistochemistry
At the end of the drug administration period, male mice (5 to 10/group) were perfused transcardially under deep anesthesia with 4% paraformaldehyde (Merck, k42072103) in 0.1 M phosphate-buffered saline, pH 7.4 (Biological Industries, 1407753). The brains were removed and placed in the same fixative at 4 °C for 4 h and then immersed in 30% sucrose in phosphate-buffered saline, pH 7.4 for 5 days at 4 °C.
Embedding
Brain tissues were embedded in tissue Tek and flash-frozen with liquid nitrogen.
Subsequently, 6-μm serial sections were cut using a cryostat mtc (SLEE Mainz, Germany) microtome at -23 °C, and sections were placed on superfrost plus slides and kept at −80 °C until use.
Immunohistochemistry
Frozen sections were air dried for 1 h and then hydrated in distilled water. (affinity-purified polyclonal rabbit IgG; Santa Cruz Biotechnology, sc11427).
Secondary antibodies were goat anti-rabbit (Vector, BA-1000) and avidin-peroxidase (Sigma, A3151). Diaminobenzidine (Sigma, D12384) was used as chromogen. Nuclear counterstaining was performed with hematoxylin (Sigma, H9627). blood levels (300 to 600 ng/ml). 
Measurements
Statistical analysis
One-way ANOVA with the Fisher least significant differences (LSD) post-hoc test on 
